000131799 001__ 131799
000131799 005__ 20241125101200.0
000131799 0247_ $$2doi$$a10.3389/fimmu.2023.1277793
000131799 0248_ $$2sideral$$a137164
000131799 037__ $$aART-2023-137164
000131799 041__ $$adeu
000131799 100__ $$aAyerdi, Oskar
000131799 245__ $$aHTLV infection in persons with sexually transmitted diseases in Spain
000131799 260__ $$c2023
000131799 5060_ $$aAccess copy available to the general public$$fUnrestricted
000131799 5203_ $$aBackground: HTLV-1 infection is a neglected disease, despite estimates of 10 million people infected worldwide and producing life-threatening illnesses in 10% of carriers. Sexual transmission is the main route of contagion. However, HTLV-1 is not listed among sexually transmitted infections (STIs).
Methods: Serum from all consecutive individuals who had attended six STI clinics across Spain during the last 12 months were tested for HTLV antibodies using a commercial enzyme immunoassay (EIA). Reactive samples were confirmed by immunoblot.
Results: A total of 2,524 samples were examined. The majority (1,936; 76.7%) belonged to men, of whom 676 (34.9%) were men who have sex with men (MSM) receiving HIV pre-exposure prophylaxis. Although native Spaniards predominated (1,470; 58.2%), up to 593 (23.5%) came from Latin America and 139 (5.5%) were African. A total of 26 individuals were initially EIA reactive and immunoblot confirmed 5 as HTLV-1 and 7 as HTLV-2. All but one HTLV-1+ case came from Latin America. Three were men and two were women. Among Latin Americans, the HTLV-1 seroprevalence was 0.67%. In contrast, all seven HTLV-2+ were native Spaniards and former injection drug users, and all but one were HIV+.
Conclusion: The rate of HTLV infection among individuals with STIs in Spain is 0.5%, which is greater than in the general population. These results support the introduction of universal HTLV screening in persons who attend clinics for STIs.
000131799 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI21-1717
000131799 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000131799 590__ $$a5.7$$b2023
000131799 592__ $$a1.868$$b2023
000131799 591__ $$aIMMUNOLOGY$$b37 / 181 = 0.204$$c2023$$dQ1$$eT1
000131799 593__ $$aImmunology and Allergy$$c2023$$dQ1
000131799 593__ $$aImmunology$$c2023$$dQ1
000131799 594__ $$a9.8$$b2023
000131799 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131799 700__ $$0(orcid)0000-0001-5134-1006$$aBenito, Rafael$$uUniversidad de Zaragoza
000131799 700__ $$aOrtega, Diego$$uUniversidad de Zaragoza
000131799 700__ $$aAguilera, Antonio
000131799 700__ $$aMontiel, Natalia
000131799 700__ $$aPintos, Ilduara
000131799 700__ $$aDíaz de Santiago, Alberto
000131799 700__ $$aBaza, Begoña
000131799 700__ $$aSoriano, Vicente
000131799 700__ $$ade Mendoza, Carmen
000131799 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000131799 773__ $$g14 (2023), 1277793 [6 pp.]$$pFront. immunol.$$tFrontiers in Immunology$$x1664-3224
000131799 8564_ $$s317748$$uhttps://zaguan.unizar.es/record/131799/files/texto_completo.pdf$$yVersión publicada
000131799 8564_ $$s1863428$$uhttps://zaguan.unizar.es/record/131799/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131799 909CO $$ooai:zaguan.unizar.es:131799$$particulos$$pdriver
000131799 951__ $$a2024-11-22-12:11:04
000131799 980__ $$aARTICLE